In-Depth Phenotyping and Research Using IMPC-Generated Knockout Mouse Strains Exhibiting Embryonic or Perinatal Lethality or Subviability (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-23-074 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. The current (July 19, 2022) IMPC data release includes...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 12, 2023 Category: Research Source Type: funding
Animal and Biological Material Resource Centers (P40) (Clinical Trials Not-Allowed)
Funding Opportunity RFA-OD-23-001 from the NIH Guide for Grants and Contracts. This FOA encourages grant applications for Animal and Biological Material Resource Centers. These Centers provide support for special colonies of laboratory animals, as well as other resources such as informatics tools, reagents, cultures (cells, tissues, and organs) and genetic stocks that serve the biomedical research community in a variety of research areas on a local, regional, and national basis. The goal of projects supported by this FOA is to provide research resources that facilitate optimization and enhancement of scientific rigor, t...
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 9, 2023 Category: Research Source Type: funding
Ancillary Studies to the NIDDK Inflammatory Bowel Disease Genetics Consortium (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-22-023 from the NIH Guide for Grants and Contracts. The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC), in collaboration with the International IBD Genetics Consortium, has identified over 250 susceptibility loci for IBD. The IBDGC has recently been renewed with a continued mission to characterize the genetic architecture of IBD phenotypes in diverse populations and to elucidate the biological mechanisms by which genetic variants influence IBD pathophysiology and clinical course. However, current resources permit functional investigation of only a limited number of loci, genes an...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 23, 2022 Category: Research Source Type: funding
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed)
Funding Opportunity PAR-23-075 from the NIH Guide for Grants and Contracts. The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) to develop a pediatric research data resource populated by genome sequence and phenotypic data that will be of high value for the communities of investigators who study the genetics of childhood cancers and/or structural birth defects. Kids First has established and continues to develop a Data Resource including a collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central port...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 23, 2022 Category: Research Source Type: funding
Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
Funding Opportunity RFA-CA-23-015 from the NIH Guide for Grants and Contracts. The goal of this FOA is to advance cancer model systems that recapitulate human immunity in the tumor microenvironment to improve the predictivity of immuno-oncology studies. Proposed research projects must focus on recapitulation of the human immune system in their proposed cancer model using human cells or tissues to regenerate and/or recapitulate the human immune system in in vivo or in vitro immuno-oncology models in a manner that matches or exceeds representation of the human immune system achieved with murine models developed using HFT....
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 22, 2022 Category: Research Source Type: funding
Clinical Studies of Mental Illness (Collaborative R01) (Clinical Trial Optional)
Funding Opportunity PAR-23-050 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to support collaborative clinical studies, not involving treatment development, efficacy, or effectiveness trials. Primary areas of focus include mental health genetics, biomarker studies, and studies of mental illnesses (e.g., psychopathology, neurodevelopmental trajectories of psychopathology) also when associated with HIV/AIDS. Applicants should apply to this FOA when two or more sites are needed to complete the study. Accordingly, the collaborating studies share a specific protocol across the...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 13, 2022 Category: Research Source Type: funding
Development of Animal Models and Related Biological Materials for Down Syndrome Research (R21 Clinical Trials Not Allowed)
Funding Opportunity PAR-23-067 from the NIH Guide for Grants and Contracts. The INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project encourages exploratory and innovative research to develop, characterize, or improve animal models and related biological materials for Down syndrome (DS) related research and to improve access to information about or from the use of animal models for DS research. The animal models and related biological materials developed must have utility in targeted or basic science studies in areas highly relevant to DS. With this funding opportunit...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 8, 2022 Category: Research Source Type: funding
Functional Validation and/or Characterization of Genes or Variants Implicated in Substance Use Disorders (R21/R33 Clinical Trial Not Allowed)
Funding Opportunity PAR-23-041 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support projects which exploit genome or epigenome editing to functionally validate and characterize genes or variants involved in substance use disorder-relevant phenotypes. It is expected that any genetic resources generated will be made broadly available to the scientific community to enable investigation of the relevant neurobiological mechanisms involved and provide critical foundational knowledge for the development of future prevention, diagnostic, and therapeutic strategies. (Source: NIH Funding Oppor...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 1, 2022 Category: Research Source Type: funding
Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional)
Funding Opportunity PAR-23-021 from the NIH Guide for Grants and Contracts. Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. NIDA has developed two Avenir Award Programs, one for HIV/AIDS research and the other for genetics or epigenetics studies. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 21, 2022 Category: Research Source Type: funding
Development of Animal Models and Related Biological Materials for Down Syndrome Research (R24 Clinical Trials Not-Allowed)
Funding Opportunity PAR-22-247 from the NIH Guide for Grants and Contracts. The INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project encourages grant applications aimed at developing, characterizing, or improving animal models and related biological materials for Down syndrome (DS) related research and improving access to information about or from the use of animal models for DS research. The animal models and related biological materials developed must have utility in targeted or basic science studies in areas highly relevant to DS. With this funding opportunity ann...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 13, 2022 Category: Research Source Type: funding
Genetic Tools for Understanding Rickettsial and Related Infections (R61/R33 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-22-047 from the NIH Guide for Grants and Contracts. A comprehensive understanding of pathogenic bacteriology requires the ability to generate and study genetically altered bacterial strains. For the obligate intracellular human pathogens of the order Rickettsialesincluding Anaplasma, Ehrilichia, Orientia and Rickettsia speciesthese tools have long lagged behind those available for extracellular bacteria. While recent advances have demonstrated the feasibility of genetically manipulating these bacteria, inherent limitations associated with their obligate intracellular nature and reduced genomes...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 3, 2022 Category: Research Source Type: funding
Building Synthetic Microbial Communities for Biology, Mitigating Climate Change, Sustainability, and Biotechnology (Synthetic Communities)
Full Proposal Deadline Date: October 3, 2022 Program Guidelines: NSF 22-607Microbes and communities of microbes have remarkable genetic, physiological and biochemical diversity, allowing them to flourish in environments all over the planet and in a variety of substrates and hosts. Given their relative importance to ecosystems around the world, to the economy and to health, researchers have studied microbial systems extensively and have a better understanding of their capabilities and impacts on hosts and the environment. In recent years, researchers have ...More at https://beta.nsf.gov/programid/506088This is an NSF Upcomi...
Source: NSF Upcoming Due Dates - September 3, 2022 Category: Science Source Type: funding
Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-22-215 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support innovative research that will inform our understanding of the mechanisms underlying the formation of structural birth defects using animal models in conjunction with human translational/clinical approaches. Applicants are encouraged to take advantage of advances in genetics, omics methods (genomics, proteomics, metabolomics, etc.), and synthetic biology, biochemical and other approaches to developmental biology research to identify specific genetic, epigenetic, environmenta...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 9, 2022 Category: Research Source Type: funding
National Institute of Allergy and Infectious Diseases (NIAID) Clinical Data and Safety Management Center (CDSMC) (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-22-058 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit applications for the NIAID CDSMC, which will support a broad range of critical support services, including data management and processing, safety and pharmacovigilance management and processing, and sample tracking systems for NIAID-funded clinical trials, integrated studies of underlying mechanisms, clinical studies (e.g., longitudinal studies, genetic studies, etc.), and studies to identify and validate surrogates/biomarkers of immune-mediated diseases in the areas of asthma and allergic diseases, autoi...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 9, 2022 Category: Research Source Type: funding
Transplantation Statistical and Clinical Coordinating Center (T-SCCC) (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-22-057 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to solicit applications for a Transplantation Statistical and Clinical Coordinating Center (T-SCCC) to provide a broad range of support critical for the design, development, execution, and analysis of clinical research carried out by multiple NIAID-supported programs in transplantation. The scope is to support the study teams with statistical design and analysis, protocol development, and final analysis of study findings. In addition, the T-SCCC will support the mechanistic studies by providing biospecimen labeling,...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 9, 2022 Category: Research Source Type: funding
